FDA rolls back N95 mask reuse to 4 decontamination cycles
The FDA has rolled back its emergency authorizations for N95 respirator decontamination systems, cutting down the number of times the agency said each mask could be safely reused.
The FDA has rolled back its emergency authorizations for N95 respirator decontamination systems, cutting down the number of times the agency said each mask could be safely reused.
HILLSBORO, Ore.— Araceli Biosciences, a provider of advanced biological imaging platforms, today announced the launch of its flagship product, the Araceli EndeavorTM. Endeavor revolutionizes drug discovery by delivering high speed, high resolution, full well scanning of cell-based assays.
Boston Scientific has obtained approval from the FDA for the fourth generation of its Vercise Genus deep brain stimulation system, allowing conditional use while within an MRI scanner.
Metastasis is responsible for most cancer-related deaths, but it’s hard to trace. Now, a group of researchers has developed a CRISPR-based method that helped track tumor spreading patterns.
Hormone therapies, or endocrine therapies, are widely used to treat breast cancer that is estrogen receptor (ER)-positive, but resistance is a common problem. That has sparked interest in drugs targeting the androgen receptor (AR). But the role of AR in ER-positive disease remains unclear, leading to the development of both AR agonists and antagonists.
Servier has partnered with MiNA Therapeutics to develop small activating RNA (saRNA) therapies in neurological disorders. The first target covered by the deal is worth up to €220 million ($267 million) to MiNA in upfront, development and commercial milestone payments.
Philips has moved to acquire Capsule Technologies—a provider of data platforms that aim to connect all of the medical devices and record systems within a hospital—to help build out its integrated care and vital sign monitoring solutions.
The FDA has accepted Incyte’s PD-1 inhibitor retifanlimab for priority review in patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC).
Ionis’ antisense oligonucleotide technology forms the backbone of three drugs to treat rare diseases. Now, the company is applying the technology to the blood cancer multiple myeloma, and it has positive results in mouse models that it says support a recently launched phase 1 trial.
After selling off its marketed cancer drug and focusing back on its pipeline after the loss of its CEO in 2019, Verastem started 2021 looking for stability in a new chief medical officer.